Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 17/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13480574 | 1.00 | EPHX1 (0.72) | EPHX1KDM4EALDH1A1EPHX2NPC1 | |
| SCHEMBL13480593 | 1.00 | EPHX1 (0.72) | EPHX1KDM4EALDH1A1EPHX2NPC1 | |
| SCHEMBL965080 | 0.98 | EPHX1 (0.69) | EPHX1KDM4EALDH1A1EPHX2NPC1 | |
| SCHEMBL968340 | 0.94 | EPHX1 (0.63) | EPHX1KDM4EALDH1A1EPHX2 | |
| SCHEMBL965926 | 0.89 | — | — | |
| SCHEMBL15263332 | 0.89 | EPHX1 (0.57) | EPHX1KDM4EALDH1A1EPHX2 | |
| SCHEMBL6357682 | 0.84 | EPHX1 (1.00) | EPHX1KDM4EALDH1A1EPHX2 | |
| SCHEMBL12196028 | 0.84 | EPHX1 (1.00) | EPHX1KDM4EALDH1A1EPHX2 | |
| SCHEMBL13062891 | 0.82 | SMN1; SMN2 (0.68) | EPHX1KDM4EALDH1A1EPHX2NPC1 | |
| SCHEMBL2751260 | 0.82 | EPHX1 (0.96) | EPHX1KDM4EALDH1A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023091554-A9 | NOVEL HETEROARYL-UREA COMPOUNDS AS KV7.2 INHIBITORS | ICAGEN, LLC (US) | 2024-05-23 | — | — | WO | disclosed |
| US-11649214-B2 | Inhibitors of the notch transcriptional activation complex kinase (“NACK”) and methods for use of the same | UNIVERSITY OF MIAMI (US) | 2023-05-16 | — | — | US | disclosed |
| US-20210171469-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX KINASE (\"NACK\") AND METHODS FOR USE OF THE SAME | UNIVERSITY OF MIAMI | 2021-06-10 | — | — | US | disclosed |
| US-10322118-B2 | Compounds and methods for inhibiting Cif virulence factor | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2019-06-18 | — | — | US | disclosed |
| EP-2426108-B1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC (CA) | 2016-08-10 | — | — | EP | disclosed |
| US-20160206605-A1 | COMPOUNDS AND METHODS FOR INHIBITING CIF VIRULENCE FACTOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-07-21 | — | — | US | disclosed |
| US-20160206605-A1 | COMPOUNDS AND METHODS FOR INHIBITING CIF VIRULENCE FACTOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-07-21 | — | — | US | disclosed |
| US-9018378-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2015-04-28 | — | — | US | disclosed |
| US-20150045389-A1 | COMPOUNDS AND METHODS FOR INHIBITING CIF VIRULENCE FACTOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-12 | — | — | US | disclosed |
| US-20150045389-A1 | COMPOUNDS AND METHODS FOR INHIBITING CIF VIRULENCE FACTOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-12 | — | — | US | disclosed |
| US-5614519-A | (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists | KARL THOMAE GMBH (DE) | 1997-03-25 | — | — | US | disclosed |
| US-5602127-A | ADMINISTERING TO TREAT HYPERTENSION | KARL THOMAE GMBH (DE) | 1997-02-11 | — | — | US | disclosed |
| US-5594003-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-14 | — | — | US | disclosed |
| US-5591762-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-07 | — | — | US | disclosed |
| US-5541229-A | ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
| US-5459147-A | Angeotensin-antagonistic effects; hypotensive, antiischemic, and antidiabetic agents, treating glaucoma | DR. KARL THOMAE GMBH (DE) | 1995-10-17 | — | — | US | disclosed |
| EP-0083096-B1 | PRODUCTION OF URETHANE COMPOUNDS | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1987-02-25 | — | — | EP | disclosed |
| US-4621149-A | PLATINUM GROUP METAL HALOGEN OR HALOGEN COMPOUND | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1986-11-04 | — | — | US | disclosed |
| EP-0083096-A2 | Production of urethane compounds | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1983-07-06 | — | — | EP | disclosed |
| US-4056527-A | HERBICIDE | BAYER AKTIENGESELLSCHAFT (DT) | 1977-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171469-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX KINASE (\"NACK\") AND METHODS FOR USE OF THE SAME | CHUK, NOTCH1, NUAK1 | EPHX1 4113/4885KDM4E 1027/4885ALDH1A1 3741/4885 |
| US-20160206605-A1 | COMPOUNDS AND METHODS FOR INHIBITING CIF VIRULENCE FACTOR | CFTR, NCF1, CFB | EPHX1 1831/4885KDM4E 4728/4885ALDH1A1 3655/4885 |
| US-10322118-B2 | Compounds and methods for inhibiting Cif virulence factor | CFTR, NCF1, CFB | EPHX1 1831/4885KDM4E 4728/4885ALDH1A1 3655/4885 |
| US-20150045389-A1 | COMPOUNDS AND METHODS FOR INHIBITING CIF VIRULENCE FACTOR | CFTR, NCF1, CFB | EPHX1 1764/4885KDM4E 4727/4885ALDH1A1 3767/4885 |
| US-11649214-B2 | Inhibitors of the notch transcriptional activation complex kinase (“NACK”) and methods for use of the same | NOTCH1, CHUK, CBFB | EPHX1 3729/4885KDM4E 916/4885ALDH1A1 3517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.